238 related articles for article (PubMed ID: 38410234)
1. Complement and coagulation cascades are associated with prognosis and the immune microenvironment of lower-grade glioma.
Yang J; Shen L; Yang J; Qu Y; Gong C; Zhou F; Liu Y; Luo M; Zhao L
Transl Cancer Res; 2024 Jan; 13(1):112-136. PubMed ID: 38410234
[TBL] [Abstract][Full Text] [Related]
2. Positive regulators of T cell functions as predictors of prognosis and microenvironment characteristics of low-grade gliomas.
Li Y; Feng Y; Luo F; Peng G; Li Y
Front Immunol; 2022; 13():1089792. PubMed ID: 36726969
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma.
Xu S; Tang L; Liu Z; Luo C; Cheng Q
Front Immunol; 2021; 12():731048. PubMed ID: 34659218
[TBL] [Abstract][Full Text] [Related]
4. Integrated analysis of inflammatory response subtype-related signature to predict clinical outcomes, immune status and drug targets in lower-grade glioma.
Cao Y; Zhu H; Chen Q; Huang H; Xie D; Li X; Jiang X; Ren C; Peng J
Front Pharmacol; 2022; 13():914667. PubMed ID: 36091778
[No Abstract] [Full Text] [Related]
5. Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in Lower-Grade Glioma.
Zhang M; Wang X; Chen X; Zhang Q; Hong J
Front Genet; 2020; 11():363. PubMed ID: 32351547
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of a Stemness Index-Associated Signature in Primary Lower-Grade Glioma.
Zhang M; Wang X; Chen X; Guo F; Hong J
Front Genet; 2020; 11():441. PubMed ID: 32431729
[TBL] [Abstract][Full Text] [Related]
7. A novel peroxisome-related gene signature predicts clinical prognosis and is associated with immune microenvironment in low-grade glioma.
Gao D; Zhou Q; Hou D; Zhang X; Ge Y; Zhu Q; Yin J; Qi X; Liu Y; Lou M; Zhou L; Bi Y
PeerJ; 2024; 12():e16874. PubMed ID: 38406287
[TBL] [Abstract][Full Text] [Related]
8. TGF-β score based on silico analysis can robustly predict prognosis and immunological characteristics in lower-grade glioma: the evidence from multicenter studies.
Zhang W; Yan Z; Zhao F; He Q; Xu H
Recent Pat Anticancer Drug Discov; 2023 Sep; ():. PubMed ID: 37718518
[TBL] [Abstract][Full Text] [Related]
9. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
10. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
11. Autophagy related DNA methylation signature predict clinical prognosis and immune microenvironment in low-grade glioma.
Qiao Q; Wang Y; Zhang R; Pang Q
Transl Cancer Res; 2022 Jul; 11(7):2157-2174. PubMed ID: 35966301
[TBL] [Abstract][Full Text] [Related]
12. Immunogenic cell death-related risk signature predicts prognosis and characterizes the tumour microenvironment in lower-grade glioma.
Cai J; Hu Y; Ye Z; Ye L; Gao L; Wang Y; Sun Q; Tong S; Yang J; Chen Q
Front Immunol; 2022; 13():1011757. PubMed ID: 36325335
[TBL] [Abstract][Full Text] [Related]
13. Construction and validation of an immune infiltration-related risk model for predicting prognosis and immunotherapy response in low grade glioma.
Li J; Guo Q; Xing R
BMC Cancer; 2023 Aug; 23(1):727. PubMed ID: 37543576
[TBL] [Abstract][Full Text] [Related]
14. Classification related to immunogenic cell death predicts prognosis, immune microenvironment characteristics, and response to immunotherapy in lower-grade gliomas.
Kuang Y; Jiang B; Zhu H; Zhou Y; Huang H; Li C; Zhang W; Li X; Cao Y
Front Immunol; 2023; 14():1102094. PubMed ID: 37153540
[TBL] [Abstract][Full Text] [Related]
15. DNMT3A promotes glioma growth and malignancy via TNF-α/NF-κB signaling pathway.
Su X; Liu J; Tu Z; Ji Q; Li J; Liu F
Transl Cancer Res; 2024 Apr; 13(4):1786-1806. PubMed ID: 38737693
[TBL] [Abstract][Full Text] [Related]
16. Development and Verification of Glutamatergic Synapse-Associated Prognosis Signature for Lower-Grade Gliomas.
Ye L; Xu Y; Hu P; Wang L; Yang J; Yuan F; Wang Y; Zhang C; Tian D; Chen Q
Front Mol Neurosci; 2021; 14():720899. PubMed ID: 34776862
[No Abstract] [Full Text] [Related]
17. CCR5 as a Prognostic Factor in Lower-Grade Glioma is Involved in the Remodeling of the Tumor Microenvironment.
Wang F; Tao Z; Tian Z; Jin J; Dong J; Dai Y; Yu W; Tang B; Hu S
Front Genet; 2022; 13():874896. PubMed ID: 35865011
[No Abstract] [Full Text] [Related]
18. Prognostic value of γ-aminobutyric acidergic synapse-associated signature for lower-grade gliomas.
Jiang H; Sun Z; Li F; Chen Q
Front Immunol; 2022; 13():983569. PubMed ID: 36405708
[TBL] [Abstract][Full Text] [Related]
19. Cuprotosis clusters predict prognosis and immunotherapy response in low-grade glioma.
Zhu W; Chen Z; Fu M; Li Q; Chen X; Li X; Luo N; Tang W; Yang F; Zhang Y; Zhang Y; Peng X; Hu G
Apoptosis; 2024 Feb; 29(1-2):169-190. PubMed ID: 37713112
[TBL] [Abstract][Full Text] [Related]
20. Identification and validation of a risk model and molecular subtypes based on tryptophan metabolism-related genes to predict the clinical prognosis and tumor immune microenvironment in lower-grade glioma.
Li W; Ling L; Xiang L; Ding P; Yue W
Front Cell Neurosci; 2023; 17():1146686. PubMed ID: 36925967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]